BeiGene
BGNE
#881
Rank
NZ$38.49 B
Marketcap
$344.02
Share price
-0.65%
Change (1 day)
1.71%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (BGNE)

Earnings in 2024 (TTM): -NZ$1.45 Billion

According to BeiGene 's latest financial reports the company's current earnings are NZ$3.09 Billion. In 2023 the company made an earning of -NZ$2.03 Billion, an increase over its 2022 earnings that were of -NZ$3 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeiGene from 2015 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -NZ$1.45 Billion-28.58%
2023 -NZ$2.03 Billion-32.52%
2022 -NZ$3 Billion24.39%
2021 -NZ$2.41 Billion-13.21%
2020 -NZ$2.78 Billion72.69%
2019 -NZ$1.61 Billion36.01%
2018 -NZ$1.19 Billion616.83%
2017 -NZ$0.17 Billion-15.24%
2016 -NZ$0.2 Billion107.91%
2015 -NZ$93.55 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-NZ$30.4 Million-97.95%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$0.41 Billion-72.40%๐Ÿ‡บ๐Ÿ‡ธ USA